Trial Profile
A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 May 2022
Price :
$35
*
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Heart failure; Hyperkalaemia
- Focus Therapeutic Use
- Acronyms PRIORITIZE HF
- Sponsors AstraZeneca; AstraZeneca AB
- 20 Jun 2020 This trial has been discontinued in Hungary, according to European Clinical Trials Database record.
- 18 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 12 Jun 2020 This trial has been discontinued in Bulgaria, according to European Clinical Trials Database record.